Moderna Inc Moderna Plans to Bring mRNA Innovation to UK
22 Juin 2022 - 8:00AM
RNS Non-Regulatory
TIDM0A45
Moderna Inc
22 June 2022
Moderna Announces Plan to Bring mRNA Innovation to the United
Kingdom
Manufacturing facility would provide access to domestically
manufactured vaccines against respiratory viruses
Moderna would expand its presence in the UK through investments
in R&D activities and capabilities
Collaboration would support the UK with direct access to rapid
pandemic response capabilities
CAMBRIDGE, MA / ACCESSWIRE / June 21, 2022 / Moderna, Inc.
(Nasdaq:MRNA), a biotechnology company pioneering messenger RNA
(mRNA) therapeutics and vaccines, today announced an agreement in
principle with the United Kingdom government to establish an mRNA
Innovation and Technology Center in the UK. This state-of-the-art
mRNA vaccine manufacturing facility is expected to provide access
to rapid pandemic response capabilities and Moderna's respiratory
virus vaccine candidates. Additionally, Moderna plans to expand its
presence in the UK through investments in research and development
(R&D) activities.
"We are excited to be able to continue our collaboration with
the UK government and Vaccine Taskforce with this new mRNA
Innovation and Technology Center in the UK. The UK has established
a world-class life sciences and research community," said Stéphane
Bancel, Chief Executive Officer of Moderna. "We are committed to
global public health, and as we continue to expand internationally,
we are pleased to bring local mRNA manufacturing to the UK. We look
forward to establishing our R&D activities and capabilities in
the country."
Moderna is committed to working with governments, health care
professionals, and other key stakeholders to meet the challenges of
the COVID-19 pandemic and future pathogens. Moderna expects its
state-of-the-art manufacturing facility to produce mRNA vaccines,
including vaccines against COVID-19, seasonal influenza,
respiratory syncytial virus (RSV), and potential other vaccines,
with the collaboration of the United Kingdom government.
The facility is intended to also be activated on an urgent basis
to support the UK with direct access to rapid pandemic response
capabilities and will support the UK in its global efforts as part
of its "100 Days Mission" to reduce the impact of future
pandemics.
The Company plans to expand its presence in the UK through
investments in R&D to complement its substantial global R&D
activities. Moderna is collaborating with the National Institute
for Health Research (NIHR) on a Phase 3 study investigating
Moderna's bivalent Omicron-containing booster candidate
(mRNA-1273.214) in the UK.
Separately, the UK government purchased 60 million doses of
Moderna's COVID-19 vaccine, which may include authorized booster
vaccine candidates for delivery in 2022 and 2023.
About Moderna
In 10 years since its inception, Moderna has transformed from a
research-stage company advancing programs in the field of messenger
RNA (mRNA), to an enterprise with a diverse clinical portfolio of
vaccines and therapeutics across seven modalities, a broad
intellectual property portfolio in areas including mRNA and lipid
nanoparticle formulation, and an integrated manufacturing plant
that allows for both clinical and commercial production at scale.
Moderna maintains alliances with a broad range of domestic and
overseas government and commercial collaborators. Most recently,
Moderna's capabilities have come together to allow the authorized
use and approval of one of the earliest and most effective vaccines
against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases, and autoimmune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past seven years. To
learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding the Company's collaboration
with the United Kingdom government to develop mRNA manufacturing
facilities in the UK; the finalization of the agreement with the
government of the UK; the types of medicines to be manufactured at
the facility and pandemic response capabilities; plans to establish
research and development capabilities in the UK; and contracts for
future sales of Moderna's COVID-19 vaccine to the UK government.
The forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond Moderna's control and which could cause actual results to
differ materially from those expressed or implied by these
forward-looking statements. These risks, uncertainties, and other
factors include those other risks and uncertainties described under
the heading "Risk Factors" in Moderna's most recent Annual Report
on Form 10-K filed with the U.S. Securities and Exchange Commission
(SEC) and in subsequent filings made by Moderna with the SEC, which
are available on the SEC's website at www.sec.gov. Except as
required by law, Moderna disclaims any intention or responsibility
for updating or revising any forward-looking statements contained
in this press release in the event of new information, future
developments, or otherwise. These forward-looking statements are
based on Moderna's current expectations and speak only as of the
date hereof.
Moderna Contacts
Media:
Luke Mircea Willats
Director, Corporate Communications
luke.mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAXFLLLLQLBBBB
(END) Dow Jones Newswires
June 22, 2022 02:00 ET (06:00 GMT)
Moderna (LSE:0A45)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Moderna (LSE:0A45)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024